ABOUT THE WORKSHOP

Antibody generation and validation can take 6-12 months, involving extensive wet lab labor and costly resource usage. Even after an elaborate antibody campaign, candidates often have developability issues, resulting in late-stage failure.

To address these inefficiencies, we present an innovative antibody screening workflow leveraging NGS and our bioinformatic platform, AbXtract™, a powerful heuristics and machine learning tool to generate a diverse list of antibody candidates for recombinant production, powered by OpenEye and developed by Specifica. This solution makes discovery and development of mAb therapies quicker and more efficient, resulting in promising biophysical profiles for commercialization.